Fifth Third Bancorp
PRTK

Fifth Third Bancorp’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Fifth Third Bancorp’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-7,000
Closed -$38K – 2481
2020
Q3 		$38K Buy
+7,000
New +$34.7K ﹤0.01% 1420

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fifth Third Bancorp's PRTK Position: Q4 2020 in Review

Fifth Third Bancorp sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2020, closing a stake of 7,000 shares — an estimated $38K sold.

Fifth Third Bancorp first reported a position in PRTK in Q3 2020 and held it in 1 quarter. The position peaked at $38K in Q3 2020. 108 funds tracked by Wall St. Rank hold PRTK as of Q4 2020.

  • Fifth Third Bancorp reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
  • Fifth Third Bancorp sold 7,000 Paratek Pharmaceuticals, Inc. shares in Q4 2020, an estimated $38K.
  • Fifth Third Bancorp first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2020 and held it in 1 quarter.
  • Fifth Third Bancorp's Paratek Pharmaceuticals, Inc. position peaked at $38K in Q3 2020.
  • 108 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2020.

Based on Fifth Third Bancorp's 13F filing for Q4 2020, filed 16 Feb 2021.